media – Page 49 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

How NMN Helps Longevity Enzymes Fight Aging

Sirtuin enzymes are a family of NAD+-dependent deacetylase proteins, also known as sirtuins, which mediate many of the beneficial effects of NMN on the brain and intestines of aged mice. Left: Sirtuin 1 bound to the sirtuin activator resveratrol (magenta). Right: Sirtuin 6 bound to the sirtuin activator (yellow) and NAD+ (red). Sirtuins act like molecular switches, orchestrating the countless processes necessary for cellular health and longevity. These specialized proteins function as NAD+-dependent deacetylases—enzymes that remove acetyl groups from other proteins, effectively altering their function. They regulate processes ranging from DNA repair and energy metabolism to inflammation and cellular stress responses. However, sirtuin activity naturally declines with aging. Sirtuins are particularly intriguing because of their dependence on NAD+ (nicotinamide adenine dinucleotide). This crucial coenzyme serves as the “fuel” for sirtuin activity. Unfortunately, NAD+ levels naturally decline with age, dropping by up to 50% in mammals during the transition from youth ...
- Source: drugdu
- 129
- August 25, 2025
Obtained U.S. FDA Drug Registration Approval for Nicardipine Hydrochloride Injection

SecuritiesDaily News Network reported on the evening of August 21 that Jianyou SharesThe company recently received an approval letter from the U.S. Food and Drug Administration (FDA) for nicardipine hydrochloride injection, 25mg/10mL (2.5mg/mL), according to an announcement. https://finance.eastmoney.com/a/202508213490940546.html
- Source: drugdu
- 89
- August 25, 2025
The world’s first hexavalent rotavirus vaccine is approved for marketing

Recently, Sinopharm Group China National Biotec Group Wuhan Biological ProductsThe Institute’s oral hexavalent, reassortant, live attenuated rotavirus vaccine (Vero cell-based) (trade name: Wushengerlunbao®) has been officially approved for marketing by the National Medical Products Administration. This product, the world’s first and most expensive rotavirus vaccine, is a Class 1 new biological drug for preventive use in China and is primarily used to prevent acute gastroenteritis in infants and young children caused by rotavirus https://finance.eastmoney.com/a/202508223492196812.html
- Source: drugdu
- 118
- August 25, 2025
【EXPERT Q&A】Are quality management systems in the medical device industry effective?

Drugdu.com expert’s response: The quality management system (QMS) in the medical device industry is not only valuable but also a core element in ensuring product safety and effectiveness, meeting regulatory requirements, enhancing corporate competitiveness, and promoting the healthy development of the industry. Its importance is reflected in the following aspects: Ensuring Patient Safety and Product Effectiveness Risk Control: Medical devices directly interact with the human body, and quality defects can lead to severe health risks (e.g., surgical instrument fractures, implant failures, diagnostic device misdiagnoses). The QMS reduces risks to acceptable levels through systematic risk assessments (e.g., Failure Mode and Effects Analysis, or FMEA), design controls, and production process monitoring. Performance Verification: Rigorous testing and validation (e.g., biocompatibility testing, electrical safety testing, performance stability testing) ensure that products meet their intended purposes and prevent medical accidents caused by functional failures. Meeting Global Regulatory and Compliance Requirements International Standard Mandates: Major global ...
- Source: drugdu
- 175
- August 25, 2025
【EXPERT Q&A】What are the registration and regulatory requirements that IVD test reagents for Chikungunya virus need to comply with?

Drugdu.com expert’s response: The registration and regulatory requirements for IVD test reagents for Chikungunya virus vary across different countries and regions. Below are the specific requirements for some major countries and regions: European Union Regulatory Compliance: Must comply with the In Vitro Diagnostic Medical Devices Regulation (IVDR, Regulation (EU) 2017/746). Product Classification: According to the classification rules of the IVDR, IVD test reagents for Chikungunya virus are typically classified as Class C or Class D, depending on their intended use and risk level. Review and Certification: For Class C or Class D products, review and certification by a Notified Body are required. Quality Management System: Companies must establish a quality management system that complies with the ISO 13485 standard and ensure that the product meets relevant basic requirements. Submission of Technical Documentation: Technical documentation, including product performance evaluation reports, clinical evidence, labels, and instructions, must be submitted. CE Marking and ...
- Source: drugdu
- 213
- August 22, 2025
Investigation raises concerns over tooth stem cell banking claims

Parents are spending thousands of pounds to bank stem cells from their children’s milk teeth – but the recipient companies’ claims about their future medical value are unproven and potentially misleading, reveals an investigation by The BMJ, published today. The companies’ claims include that stem cells banked from teeth are already being used in treatments for autism and diabetes. They also highlight current research using stem cells in multiple sclerosis, Parkinson’s disease, and heart attacks. Tooth stem cell banking involves parents sending their children’s lost milk teeth to a laboratory where the dental pulp stem cells are harvested and stored. The service costs around £1900 (€2189; $2573) with an additional annual storage fee of £95, explains freelance journalist Emma Wilkinson. The three companies in the UK offering tooth stem cell banking – Future Health Biobank, BioEden and Stem Protect – all operate through one laboratory. Future Health Biobank says on ...
- Source: drugdu
- 134
- August 21, 2025
Seniors Neglecting Steps To Protect Heart Health, Study Says

By Dennis Thompson HealthDay ReporterWEDNESDAY, Aug. 20, 2025 (HealthDay News) — Seniors with known heart-related problems aren’t doing a very good job taking steps to protect their health, a new study says. Older folks with high blood pressure, stroke survivors and heart failure patients in the United States all have been neglecting Life’s Essential 8 — a checklist of lifestyle factors that can protect heart health, researchers found. “On average, participants with one cardiovascular disease had a Life’s Essential 8 score 9 points lower than those without cardiovascular disease,” lead researcher James Walker, a medical student at Northwestern University in Chicago, said in a news release. Life’s Essential 8 recommends that people eat healthy, exercise, avoid smoking, sleep better, lose excess weight, and manage their cholesterol, blood sugar and blood pressure levels, according to the American Heart Association. For this study, researchers analyzed a sample of more than 3,000 adults ...
- Source: drugdu
- 109
- August 21, 2025
Pfizer’s $5.4 billion gamble fails

Recently, Pfizer announced that its key sickle cell disease drug inclacumab failed to reach the primary endpoint in the phase III THRIVE-131 study. This news casts a shadow over Pfizer’s layout in this field. The Phase III THRIVE-131 study was designed to evaluate the effect of inclacumab in reducing vaso-occlusive crises. The results of the study showed that there was no significant difference in the incidence of vascular occlusive crisis between the inclacumab group and the placebo group, and inclacumab failed to achieve a statistically significant effect. Sickle cell disease (SCD) is a hereditary blood disorder in which red blood cells are sickle-shaped due to abnormalities in hemoglobin molecules, affecting blood flow and oxygen delivery. Patients often have symptoms such as pain and anemia, and may face many difficulties in life due to sudden illness, which brings a heavy burden to patients and families. Looking back at Pfizer’s layout of ...
- Source: drugdu
- 95
- August 21, 2025
InnoCare Pharma’s new anticancer drug Mesutoclax completes first patient dosing in clinical trial

InnoCare Pharma announced on August 21 that the first patient was dosed in the registrational clinical trial of the company’s independently developed novel BCL2 inhibitor Mesutoclax (ICP-248) for the treatment of mantle cell lymphoma (MCL) previously treated with BTK inhibitors. Mesutoclax is a novel, oral, highly selective BCL2 inhibitor. BCL2 is a key regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development and progression of various hematological malignancies. Mesutoclax selectively inhibits BCL2, restoring the programmed cell death mechanism in tumor cells, thereby exerting its anti-tumor efficacy. This unique mechanism of action holds great potential for the treatment of MCL, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other indications. InnoCare Pharma is currently advancing clinical trials for these indications globally. This registrational clinical trial is designed to evaluate the safety and efficacy of mesutoclax in patients with MCL ...
- Source: drugdu
- 111
- August 21, 2025
Novartis’ innovative drug Noradrena approved for IgA nephropathy in China

On August 20, Novartis Group announced that its innovative product, Noradrena® (atrasentan hydrochloride tablets), has received approval from the National Medical Products Administration (NMPA) for the reduction of proteinuria in adult patients with primary immunoglobulin A nephropathy (IgA nephropathy) at risk of rapid disease progression. Noradrena is reportedly the first non-immunological therapy approved in China for the treatment of IgA nephropathy and the first and currently only highly selective endothelin A (ETA) receptor antagonist for this indication. https://finance.eastmoney.com/a/202508203489375117.html
- Source: drugdu
- 143
- August 21, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.